Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

References

• Alexander DJ, Collins CJ, Coombs DW, et al. (2008). Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol 20:1179–89.
   PubMed Web of Science ®Google Scholar
• Allen JW, Moon J, Redman M, et al. (2014). Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463–70.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Grimes MJ, Picchi MA, et al. (2011). Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 71:454–62.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. (2017). First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–26.
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Pujol JL, et al. (2007). Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–92.
   PubMed Web of Science ®Google Scholar
• Elkins MR, Anderson SD, Perry CP, et al. (2014). Inspiratory flows and volumes in subjects with non-CF bronchiectasis using a new dry powder inhaler device. Open Respir Med J 8:8–13.
   PubMedGoogle Scholar
• Gagnadoux F, Hureaux J, Vecellio L, et al. (2008). Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 21:61–70.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. (2014). Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev 75:18–31.
   PubMed Web of Science ®Google Scholar
• Jones S, Thompson D, Barton J, et al. (2008). A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 9:154–9.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Kris MG, Smith IE, et al. (1998). Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol 21:438–41.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Ji H, Yuza Y, et al. (2005). An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65:7096–101.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665–70.
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. (2016). Respiratory tract deposition of HFA-beclomethasone and HFA-fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv 29:127–33.
   PubMed Web of Science ®Google Scholar
• Lynch TJ Jr, Kalish L, Strauss G, et al. (1994). Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347–52.
   PubMed Web of Science ®Google Scholar
• Mangal S, Gao W, Li T, et al. (2017). Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin 38:782–97.
   PubMed Web of Science ®Google Scholar
• March TH, Marron-Terada PG, Belinsky SA. (2001). Refinement of an orthotopic lung cancer model in the nude rat. Vet Pathol 38:483–90.
   PubMed Web of Science ®Google Scholar
• Masuda N, Matsui K, Negoro S, et al. (2010). Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. Clin Lung Cancer 11:271–9.
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, et al. (2017). PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett 405:29–37.
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Adichwal SA, Gaikwad KR, et al. (2011). Pulmonary drug delivery: novel pharmaceutical technologies breathe new life into the lungs. PDA J Pharm Sci Technol 65:513–34.
   PubMedGoogle Scholar
• Nichols L, Saunders R, Knollmann FD. (2012). Causes of death of patients with lung cancer. Arch Pathol Lab Med 136:1552–7.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Eckardt J, Ramlau R. (2007). Recent advances with topotecan in the treatment of lung cancer. Oncologist 12:1194–204.
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Ciuleanu TE, Tsekov H, et al. (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–7.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–80.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Fossella FV, Glisson BS, et al. (1996). Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503–13.
   PubMed Web of Science ®Google Scholar
• Ramlau R, Gervais R, Krzakowski M, et al. (2006). Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24:2800–7.
   PubMed Web of Science ®Google Scholar
• Reed MD, Tellez CS, Grimes MJ, et al. (2013). Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 109:1775–81.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Tessema M, Yingling CM, Thomas CL, et al. (2012). SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31:4107–6.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. (2005). Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 172:1497–504.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. (2014). Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32:4012–9.
   PubMed Web of Science ®Google Scholar
• Weitz JJ, Marschke RF, Jr., Sloan JA, et al. (2000). A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28:157–62.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Tang P, Leung SS, et al. (2014). Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev 75:3–17.
   PubMed Web of Science ®Google Scholar